Form 4: Amylyx Pharmaceuticals CFO James M. Frates Receives Stock Options and Restricted Stock Units

Chief Financial Officer James M. Frates of Amylyx Pharmaceuticals received stock options and restricted stock units, as detailed in a recent SEC filing.

Summary

• James M. Frates, CFO of Amylyx Pharmaceuticals, received a grant of 91,180 restricted stock units (RSUs) on April 16, 2024.
• These RSUs will vest in three tranches: 33% on September 30, 2024, 33% on March 31, 2025, and 34% on September 30, 2025, contingent upon continued service to the company.
• Frates also received an option to purchase 120,000 shares of common stock at an exercise price of $2.01 per share.
• 25% of these options will vest on April 16, 2025, with the remaining shares vesting monthly over the subsequent 36 months, also subject to continued service.
• Following these transactions, Frates directly owns 225,964 shares of Amylyx common stock.
• He also has indirect ownership through trusts: 15,459 shares via the James M. Frates 2024 Grantor Retained Annuity Trust No. 1 and 11,072 shares via the FRATES FAMILY 2013 IRREV TRUST.
• Frates disclaims beneficial ownership of the shares held by the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options aligns the CFO's interests with the long-term success of Amylyx Pharmaceuticals.
• The vesting schedules for both the RSUs and stock options incentivize continued service and commitment from the CFO.

Industry Context

This type of equity compensation is standard practice for publicly traded pharmaceutical companies to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants are a common component of executive compensation packages in the pharmaceutical industry.
• Companies like Biogen, Vertex Pharmaceuticals, and Regeneron also utilize stock options and RSUs to align executive incentives with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• The equity grants aim to align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates